Navigation Links
Cubist Pharmaceuticals Applauds Congressman Gingrey for Introducing Legislation to Help Fight Superbug Infections
Date:6/16/2011

LEXINGTON, Mass., June 16, 2011 /PRNewswire-USNewswire/ -- Cubist Pharmaceuticals, Inc. today praised Rep. Phil Gingrey, R-Ga., and co-sponsors for introducing the Generating Antibiotic Incentives Now (GAIN) Bill of 2011. This critical piece of legislation was crafted to help restore a robust antibiotic development pipeline to address the growing public health threat due to emerging multi-drug-resistant (MDR) bacteria.

The bi-partisan legislation calls for the enactment of specific economic and market incentives to entice pharmaceutical companies to develop new antibiotics to treat the growing number of serious infections caused by MDR bacteria. For example, the legislation's provision for extending the exclusivity granted to some badly-needed antibiotics is designed to have the same impact on antibiotic R&D as the Orphan Drug Act had on drugs to treat rare diseases, which now enjoy a healthy pipeline.

"Cubist Pharmaceuticals applauds Congressman Gingrey and his colleagues for their foresight in bringing the GAIN Bill forward," said Michael Bonney, President and CEO of Cubist Pharmaceuticals. "The antibiotic development pipeline is in danger of running dry.  Without policies to reverse this market failure, our public health system is at risk of increased treatment costs in the vicinity of $20 billion a year. In addition, our national security can be vulnerable to a bio-terrorist attack using antibiotic-resistant organisms."

The Infectious Diseases Society of America (IDSA), which represents physicians, scientists and other health care professionals who specialize in infectious diseases, estimates there are 100,000 U.S. deaths each year from hospital-acquired infections due mostly to antibiotic-resistant pathogens. To help spur the pipeline, IDSA released the "Bad Bugs Need Drugs 10x20" plan, an initiative promoting the introduction of 10 new antibiotics into the U.S. market by 2020. The GAIN Bill supports this goal by bringing new i
'/>"/>

SOURCE Cubist Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution
2. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 Every year ... research to fight heart disease.  Nevertheless, year after year ... ElectroCardioGrams (EKG) as the first test to determine the ... have chest pain or not, even though that technology ... despite the fact that doctors know, (while most patients ...
(Date:2/26/2015)... Mass. , Feb. 26, 2015  Spring ... novel therapeutics for the treatment of Hepatitis B ... the closing of a $22 million financing. Funds ... SB 9200, a novel, broad spectrum antiviral agent ... nucleic acid hybrid (SMNH) chemistry platform, into Phase ...
(Date:2/26/2015)... 26, 2015  Lyric Pharmaceuticals Inc. today announced the ... $20.4 million. The financing, co-led by RiverVest Venture Partners, ... Aperture Venture Partners. Lyric is a ... Wurtman , M.D., M.B.A., President & Chief Executive Officer ... Officer.  In 2014, Lyric closed a seed financing round ...
Breaking Medicine Technology:National Heart Health Month In February 2Spring Bank Pharmaceuticals Completes $22 Million Financing 2
... NEW YORK, Sept. 13, 2011 IMMUNE ... based Therapeutics for the treatment of inflammatory diseases and ... M.D., Ph.D., to the position of Chief Medical Officer.  ... pivotal  role in the development of Bertilimumab, IMMUNE,s phase ...
... DIEGO, Sept. 13, 2011 Sequenom, Inc. (NASDAQ: ... solutions, today announced the Company,s participation at the UBS Global ... in New York City September 19-21, 2011. ... Development, will present on Monday, September 19, 2011 beginning at ...
Cached Medicine Technology:IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 2IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 3Sequenom Announces Participation at UBS Global Life Sciences Conference 2
(Date:2/27/2015)... VA (PRWEB) February 27, 2015 The ... accepting applications for its next class of Fellows — ... field of radiology business management. , Since 2009, ... significant contributions made by RBMA members to the Association ... a prestigious recognition because each Fellow candidate must meet ...
(Date:2/27/2015)... The report “Polycystic Ovarian Syndrome ... on the therapeutic development for polycystic ovarian syndrome. ... a woman's hormones are out of balance. Polycystic ... girls and young women. The cause of polycystic ... pipelines by identifying new targets and MOAs to ...
(Date:2/27/2015)... February 27, 2015 Prescription Drug ... U.S. Drug Enforcement Agency (DEA). Today, ... continue to utilize the “Take-Back” guidelines for the ... FDA. , Eufaula Prescription Drug Disposal Event , ... Drive in Eufaula, Oklahoma as the “Take-Back” site ...
(Date:2/27/2015)... 27, 2015 ResearchMoz has announced ... the analysis of the cell culture protein surface ... discusses the current scenario and development prospects of ... for the period of 2015 to 2019. , ... , The research report, titled Global Cell ...
(Date:2/27/2015)... VT (PRWEB) February 27, 2015 The ... mitigation plan for alleged violations that date back to ... department was completed as soon as it was approved ... Hermitage didn't agree with the allegations we agreed to ... Hermitage Inn Real Estate Holding Company. , Barnes further ...
Breaking Medicine News(10 mins):Health News:RBMA Issues Call for Fellowship Applicants 2Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 2Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 3Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 4Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 2Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 3Health News:Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth 2Health News:Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth 3Health News:Southern Vermont's Hermitage Club Announces Statement Regarding Vermont Attorney General Lawsuit for Permit Violations 2
... (NYSE: HUN ) will hold a conference call to discuss its ... 11:00 a.m. ET. Fourth quarter and full year 2007 results will be,released ... Call-in number for U.S. participants: ... Call-in number for international participants: (617) 213 - 4868 ...
... Spending Cuts, ALEXANDRIA, Va., Feb. 8 President ... to the future of,health and health care for all ... the nation,s single largest payer of children,s health care ... from,discretionary health programs that children depend on, ranging from ...
... Despite Difficulties, States Rise Against the Status Quo ... - A new report from the,Robert Wood Johnson ... 2008: Rising to the Challenge, outlines 2007 efforts ... to address health care,reform at the state level. ...
... NHS Choices ( http://www.nhs.uk ), the,online ,front ... news service to,help people make sense of the ... Behind the headlines, on NHS Choices,( http://www.nhs.uk/News/Pages/NewsIndex.aspx ), ... the news. The service explains the,facts behind newspaper ...
... Feb. 8 The Integrated,Healthcare Association (IHA) welcomes ... third annual National Pay for Performance Summit at ... summit is the,leading forum on pay for performance ... Leapfrog Group has made outstanding contributions toward the,improvement ...
... finds spouses die sooner in unions where anger is suppressed ... secret to a long marriage is communication, and new research ... , A lengthy study of Midwestern couples finds that those ... the perennially resentful. The couples with the most unexpressed anger ...
Cached Medicine News:Health News:Huntsman to Discuss Fourth Quarter and Full Year 2007 Results on Friday, February 22, 2008 2Health News:Bush Budget Cuts Federal Health Programs Vital to the Health of All Children 2Health News:Bush Budget Cuts Federal Health Programs Vital to the Health of All Children 3Health News:Report Lists Key Policy Questions Facing State, National Health Reform 2Health News:Report Lists Key Policy Questions Facing State, National Health Reform 3Health News:Report Lists Key Policy Questions Facing State, National Health Reform 4Health News:Integrated Healthcare Association Welcomes Leah Binder, New CEO of Leapfrog Group to National Pay for Performance Summit 2Health News:Mutual Resentment in Marriage Can Be Deadly 2Health News:Mutual Resentment in Marriage Can Be Deadly 3
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
Medicine Products: